HBPCF (Helix BioPharma) Ending Cash Position: $2.05 Mil (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Ending Cash Position?

Helix BioPharma HBPCF 28 Ending Cash Position is $2.05 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Helix BioPharma's Ending Cash Position for the quarter that ended in Apr. 2026 was $2.05 Mil.

Helix BioPharma's quarterly Ending Cash Position declined from Oct. 2025 ($0.36 Mil) to Jan. 2026 ($0.02 Mil) but then increased from Jan. 2026 ($0.02 Mil) to Apr. 2026 ($2.05 Mil).

Helix BioPharma's annual Ending Cash Position increased from Jul. 2023 ($0.61 Mil) to Jul. 2024 ($0.79 Mil) but then declined from Jul. 2024 ($0.79 Mil) to Jul. 2025 ($0.05 Mil).

Helix BioPharma Ending Cash Position Related Terms

Helix BioPharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Ending Cash Position Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.85 2.51 0.61 0.79 0.05

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.05 0.36 0.02 2.05
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Helix BioPharma's Ending Cash Position for the fiscal year that ended in Jul. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.789+-0.742
=0.05

Helix BioPharma's Ending Cash Position for the quarter that ended in Apr. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.023+2.03
=2.05

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.05 Mil mean?
Helix BioPharma (HBPCF) has a Ending Cash Position of $2.05 Mil as of Apr. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Ending Cash Position too high?
Helix BioPharma's current Ending Cash Position is $2.05 Mil. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Ending Cash Position compare to VRTX and REGN?
Helix BioPharma's Ending Cash Position of $2.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Ending Cash Position is $2.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Ending Cash Position of $2.05 Mil. The current Ending Cash Position is $2.05 Mil. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Ending Cash Position is $2.05 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price